Convalescent plasma treatment for SARS-CoV-2 infection: analysis of the first 436 donors in England, 22 April to 12 May 2020.
Adolescent
Adult
Aged
Antibodies, Neutralizing
/ blood
Antibody Specificity
Betacoronavirus
/ immunology
Blood Donors
/ statistics & numerical data
COVID-19
Coronavirus Infections
/ blood
England
Humans
Immunization, Passive
/ statistics & numerical data
Middle Aged
Pandemics
Pneumonia, Viral
/ blood
SARS-CoV-2
Statistics, Nonparametric
Time Factors
Young Adult
COVID-19 Serotherapy
SARS-CoV-2
antibody response
convalescent plasma
high titre
neutralising antibodies
symptomatic infection
Journal
Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin
ISSN: 1560-7917
Titre abrégé: Euro Surveill
Pays: Sweden
ID NLM: 100887452
Informations de publication
Date de publication:
Jul 2020
Jul 2020
Historique:
entrez:
24
7
2020
pubmed:
24
7
2020
medline:
30
7
2020
Statut:
ppublish
Résumé
Serological reactivity was analysed in plasma from 436 individuals with a history of disease compatible with COVID-19, including 256 who had been laboratory-confirmed with SARS-CoV-2 infection. Over 99% of laboratory-confirmed cases developed a measurable antibody response (254/256) and 88% harboured neutralising antibodies (226/256). Antibody levels declined over 3 months following diagnosis, emphasising the importance of the timing of convalescent plasma collections. Binding antibody measurements can inform selection of convalescent plasma donors with high neutralising antibody levels.
Identifiants
pubmed: 32700670
doi: 10.2807/1560-7917.ES.2020.25.28.2001260
pmc: PMC7376844
doi:
Substances chimiques
Antibodies, Neutralizing
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Investigateurs
Stephen Thomas
(S)
Sheila MacLennan
(S)
Lise Estcourt
(L)
Su Brailsford
(S)
Hatice Baklan
(H)
Kate Tettmar
(K)
Jeremy Kellington
(J)
Joanne Sell
(J)
Gail Miflin
(G)
Commentaires et corrections
Type : ErratumIn
Références
Clin Infect Dis. 2020 Jun 04;:
pubmed: 32497196
Clin Infect Dis. 2020 Jul 28;71(15):778-785
pubmed: 32198501
JAMA. 2020 Mar 27;:
pubmed: 32219428
Clin Infect Dis. 2020 Mar 28;:
pubmed: 32221519
Euro Surveill. 2020 Jun;25(23):
pubmed: 32553061
Nat Microbiol. 2020 Apr;5(4):536-544
pubmed: 32123347
Emerg Infect Dis. 2020 Jul;26(7):1478-1488
pubmed: 32267220
Transfus Med. 2020 Jun;30(3):174-176
pubmed: 32447783
Euro Surveill. 2020 May;25(18):
pubmed: 32400364
Nat Med. 2020 Jun;26(6):845-848
pubmed: 32350462
J Infect Dis. 2014 Apr 1;209(7):995-1006
pubmed: 24253287
Proc Natl Acad Sci U S A. 2020 Apr 28;117(17):9490-9496
pubmed: 32253318
Autoimmun Rev. 2020 Jul;19(7):102554
pubmed: 32380316